Clinical Trial

A Phase 3 Study to Evaluate the Efficacy and Safety of MGL-3196 (Resmetirom) in Patients With NASH and Fibrosis (MAESTRO-NASH)

Study Status:

Contact Information:

Please contact us for more information or to learn if you are eligible to participate.

Study Purpose

The purpose of this medical research study is to determine the effect of once-daily, oral administration of 80 or 100 mg MGL-3196 versus matching placebo on NASH (a placebo looks like the investigational drug but does not contain any of the active ingredients of the investigational drug). The study is open to male and female participants 18 years of age or older who meet the study requirements.

Information

Principal Investigator Rashmee Patil, MD
Co-PI
Sponsor Madrigal Pharmaceuticals, Inc
Type of Trial Interventional